Thus, PD1+ and PD-L1+ granulocyte percentages were quantified and tested as possible predictive biomarkers in the setting of atezolizumab–bevacizumab treatment in HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.